| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 641.6 | 776.3 | 292.8 |
| Other income | 8.5 | 12.5 | 7.9 |
| Total income | 650.1 | 788.7 | 300.6 |
| Profit before exceptional items & tax | 197.8 | 287.5 | 17.6 |
| Profit before tax | 197.8 | 287.5 | 17.6 |
| Net profit | 147.7 | 212.7 | 13.9 |
| Operating margin | 30.4% | 36.5% | 5.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +962.60% |
|---|---|
| Net profit, quarter on quarter | -30.60% |
| Revenue, year on year | +119.10% |
| Operating profit, year on year | +1851.50% |
| Operating profit, quarter on quarter | -31.20% |
NSE results filing, NSE: NEULANDLAB. Figures extracted from the filing.
Neuland Laboratories Ltd: key numbers
- Share price
- ₹21,890.00
- Market cap
- ₹28,085 Cr
- Revenue (annual)
- ₹2,023 Cr
- Net profit (annual)
- ₹364.0 Cr
- P/E (TTM)
- 56.4×Sector 50.4×
- Promoter holding
- 32.62%-0.01% QoQ
- FII holding
- 21.08%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Neuland Laboratories Ltd
All →Neuland Laboratories Production Started
Neuland commissioned its first commercial peptide manufacturing module with 7,000L reactor capacity. Module two expansion is underway to meet rising customer demand for peptide APIs.
- peptide manufacturing reactor capacity
- 7000 L
Neuland Laboratories Capacity Expansion: ₹126 Cr Investment
Neuland Laboratories' board approved ₹126 Crore capex to acquire 134 acres of land in Andhra Pradesh for future expansion. The company holds ROFR on additional land.
- Value
- ₹126.0 Cr
- land acquisition
- 134.0 acres
Neuland Laboratories Earnings Call Transcript: Key Takeaways
Q1FY27 was broadly in line with expectations, showing strong YoY revenue and profit growth. Management remains confident in achieving a 20% growth rate despite inherent quarterly volatility in the CMS business.
- Call
- Guides 20% growth
Neuland Laboratories Investor Presentation: Key Takeaways
Neuland reported Q1FY27 total income of ₹650.1 Cr (116.3% YoY growth) with an EBITDA margin of 35.5%. Growth is driven by the CMS business and commercial molecules.
Neuland Laboratories Earnings Call: Key Takeaways
Neuland reported record performance for Q4FY26, driven by high-value CMS commercial projects and favorable exchange rates, achieving an exceptional 40.5% EBITDA margin.
Neuland Laboratories Earnings Call: Key Takeaways
Neuland Laboratories' March 2026 API Product List showcases a robust portfolio across diverse therapeutic segments including anticoagulants, antipsychotics, and peptides.